| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash (used in)/provided by investing activities | -236,121 | 0 |
| Proceeds from issuance on common stock, net of issuance costs | 0 | - |
| Proceeds from exercise of options | 1,031 | 595 |
| Payment for deferred offering costs | - | 0 |
| Net cash provided by financing activities | 1,031 | 595 |
| Net (decrease)/increase in cash and cash equivalents | -318,038 | -53,105 |
| Cash and cash equivalents at beginning of period | 489,711 | - |
| Cash and cash equivalents at end of period | 171,673 | - |
Bicara Therapeutics Inc. (BCAX)
Bicara Therapeutics Inc. (BCAX)